Treatment for hepatitis C virus-associated mixed cryoglobulinaemia.
CONCLUSIONS: To treat HCV-associated mixed cryoglobulinaemia, it may be beneficial to eliminate HCV infection by using antiviral treatment and to stop the immune response by using rituximab. For skin vasculitis and for some laboratory findings, it may be appropriate to combine antiviral treatment with deletion of B-cell clonal expansions by using of rituximab. The applicability of evidence reviewed here is limited by the absence of any studies with direct-acting antivirals, which are urgently needed to guide therapy.
PMID: 29734473 [PubMed - as supplied by publisher]
Source: Cochrane Database of Systematic Reviews - Category: General Medicine Authors: Montero N, FavĂ A, Rodriguez E, Barrios C, Cruzado JM, Pascual J, Soler MJ Tags: Cochrane Database Syst Rev Source Type: research
More News: Antiviral Therapy | Brain | Clinical Trials | Conferences | Databases & Libraries | General Medicine | Glomerulonephritis | Hepatitis | Hepatitis C | Kidney Transplant | Kidney Transplantation | Laboratory Medicine | Liver | Liver Transplant | Lung Transplant | Lymphoma | Neurology | Peripheral Neuropathy | Proteinuria | Rheumatology | Rituxan | Skin | Statistics | Study | Transplant Surgery | Transplants | Urology & Nephrology | Vasculitis